Fosamax Osteonecrosis of the Jaw Attorney: Statute of Limitations for Fosamax in Texas

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Awareness to Targeted Risk Assessment

For decades, general health and science communication has served as the foundation for public understanding of medical risks and therapeutic benefits. This legacy context emphasized broad awareness of how medications interact with biological systems, often focusing on common side effects and preventive care. Within this framework, audiences became accustomed to evaluating health information through a lens of general wellness, where the primary concern was maintaining overall bodily function and avoiding widely recognized adverse events. As this informational heritage evolved, a more specialized area of concern emerged: the relationship between long-term pharmaceutical exposure and specific tissue responses. In particular, the bisphosphonate class of drugs, widely prescribed for bone density management, prompted closer scrutiny of their effects on oral and maxillofacial structures. This shift moved the conversation from general health maintenance to a more targeted occupational and environmental exposure paradigm. The transition becomes most apparent when considering how patients and practitioners now assess risk not merely in terms of systemic side effects, but through the lens of cumulative exposure duration and anatomical vulnerability. What was once a broad discussion of medication safety has narrowed to focus on the conditions under which prolonged drug presence in bone tissue may lead to localized complications. This pivot reframes the legacy of general health science into a practical concern for those with sustained pharmaceutical exposure, particularly in contexts where treatment duration and patient history become critical variables in risk assessment.

Understanding Fosamax and Its Link to Osteonecrosis of the Jaw

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The time to onset of symptoms of ONJ after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The incidence of ONJ is considered rare, and atypical femoral fracture or ONJ were uncommon and rare respectively in one study (https://pubmed.ncbi.nlm.nih.gov/42046648/). Fragility fracture was not associated with interruption of bisphosphonate prescription for up to two years, after either three or five years of prescription (https://pubmed.ncbi.nlm.nih.gov/42046648/).

Mechanistic Pathways and Warning Adequacy

The mechanistic pathways linking Fosamax to ONJ involve the drug's action on bone remodeling. Bisphosphonates like Fosamax inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jaw, which has high bone turnover rates and is subject to microtrauma from chewing, this suppression may impair the ability to repair microdamage and heal after dental procedures. This can lead to avascular necrosis, where bone tissue dies due to lack of blood supply, particularly when combined with local infection or trauma. The exact mechanism is not fully understood, but it is believed that bisphosphonate accumulation in the jawbone, combined with factors like dental disease or invasive procedures, contributes to ONJ development. Regarding the adequacy of warnings, the Fosamax label includes a specific section on Osteonecrosis of the Jaw (Section 5.4) that describes the condition, its association with bisphosphonates, and known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label does not provide specific guidance on the statute of limitations for legal claims, which is a separate legal matter.

Legal Considerations for Texas Patients: Statute of Limitations

For affected patients in Texas, attorney-related considerations include the statute of limitations for filing a lawsuit regarding Fosamax-related ONJ. In Texas, the statute of limitations for personal injury claims, including those related to defective drugs, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is critical because the onset of ONJ symptoms can vary from one day to several months after starting Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), and the condition may be diagnosed months or years after exposure. Patients who develop ONJ should seek legal advice promptly to ensure they do not miss the filing deadline. The timeline between exposure to Fosamax and documented harm can be prolonged, as ONJ may develop after years of bisphosphonate use, and the risk may increase with duration of exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). This delay can complicate the determination of when the statute of limitations begins to run. In summary, Fosamax is associated with a rare but serious risk of ONJ, particularly in patients with risk factors such as invasive dental procedures or prolonged use. The drug's label includes warnings about this risk, but patients in Texas should be aware of the two-year statute of limitations for filing claims. The variable onset of symptoms and potential for delayed diagnosis underscore the importance of timely legal consultation for affected individuals.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Fosamax-related ONJ claims in Texas?

In Texas, the statute of limitations for personal injury claims, including those related to defective drugs like Fosamax, is generally two years from the date the injury was discovered or should have been discovered with reasonable diligence. Because ONJ symptoms can appear months or years after exposure, it is crucial to consult an attorney promptly to avoid missing the deadline.

What are the known risk factors for developing ONJ from Fosamax?

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures). The risk may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.